camostat and leucine

camostat has been researched along with leucine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Drosten, C; Erichsen, S; Herrler, G; Herrler, T; Hoffmann, M; Kleine-Weber, H; Krüger, N; Müller, MA; Nitsche, A; Pöhlmann, S; Schiergens, TS; Schroeder, S; Wu, NH	1
Ledford, H	1

Other Studies

2 other study(ies) available for camostat and leucine

Article	Year
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; Cell Line; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Development; Esters; Gabexate; Guanidines; Humans; Immunization, Passive; Leucine; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protease Inhibitors; Receptors, Virus; SARS-CoV-2; Serine Endopeptidases; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Vesiculovirus; Virus Internalization	2020
Hundreds of COVID trials could provide a deluge of new drugs. Nature, 2022, Volume: 603, Issue:7899 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication	2022

Article

Year

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell, 2020, 04-16, Volume: 181, Issue:2

Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; Cell Line; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Development; Esters; Gabexate; Guanidines; Humans; Immunization, Passive; Leucine; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protease Inhibitors; Receptors, Virus; SARS-CoV-2; Serine Endopeptidases; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Vesiculovirus; Virus Internalization

2020

Hundreds of COVID trials could provide a deluge of new drugs.

Nature, 2022, Volume: 603, Issue:7899

Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication

2022